Alloga (nederland) B.v.

Alloga (Nederland) B.V., established in 1998, is a Dutch company specializing in logistics services, particularly within the pharmaceutical sector. Headquartered at De Amert 603, 5462 GH Veghel, Netherlands, it operates under the legal form of a Besloten Vennootschap (private limited company) with registration number 17108476. The company is part of the Alloga network, a pan-European pharmaceutical logistics provider, offering services tailored to the specific requirements of each country or region.

Alloga (Nederland) B.V. plays a significant role in the Netherlands' pharmaceutical distribution chain by providing comprehensive logistics solutions. These services include storage, order fulfillment, packaging, and distribution of pharmaceutical products, ensuring compliance with Good Manufacturing Practice (GMP) standards. (alloga.nl) The company's expertise extends to handling both prescription and over-the-counter medications, catering to various stakeholders such as pharmacies, hospital groups, and healthcare providers.

Alloga (Nederland) B.V. operates a centralized distribution center located at De Amert 603, 5462 GH Veghel, Netherlands. This facility is strategically positioned to serve the Benelux region, encompassing Belgium, the Netherlands, and Luxembourg. The company's logistics capabilities are designed to ensure efficient storage and distribution of pharmaceutical products, adhering to stringent regulatory standards. While specific details about additional warehouse locations or geographic coverage beyond the Benelux region are not publicly disclosed, Alloga's affiliation with the pan-European Alloga network suggests potential access to a broader distribution infrastructure across Europe.

Alloga (Nederland) B.V. functions primarily as a logistics intermediary within the Netherlands' pharmaceutical supply chain. Its core activities include the storage, packaging, and distribution of pharmaceutical products, ensuring that medications reach their intended destinations in compliance with regulatory standards. The company's services are integral to the efficient operation of the pharmaceutical sector, supporting various stakeholders such as pharmaceutical manufacturers, wholesalers, and healthcare providers. By managing the complexities of pharmaceutical logistics, Alloga (Nederland) B.V. contributes to the overall effectiveness and reliability of the supply chain.

Alloga (Nederland) B.V. imports finished pharmaceutical formulations from India, with a total import value of $1.5 million USD across 64 shipments. The product portfolio comprises three products across three therapeutic categories, with the top five products accounting for 100% of the imports. This indicates a high level of concentration in sourcing, which could pose risks such as supply chain disruptions or dependency on a limited number of suppliers. However, the strategic choice to focus on a select range of products may also allow for streamlined operations and specialized expertise in these areas. The stability of the relationship with Indian suppliers is crucial, and the consistent import pattern over the years suggests a reliable and ongoing partnership.

The resilience of Alloga (Nederland) B.V.'s supply chain is closely tied to its relationship with Indian suppliers. The company's focus on a limited number of products imported from India suggests a strategic sourcing approach, potentially allowing for better quality control and cost management. However, this concentration also means that any disruptions in the Indian supply chain—such as regulatory changes, production issues, or logistical challenges—could significantly impact Alloga's operations. To mitigate these risks, it would be prudent for Alloga to establish contingency plans, including identifying alternative suppliers and diversifying its product range. Ensuring that key suppliers comply with international regulatory standards, such as Good Manufacturing Practice (GMP), is essential for maintaining the integrity and reliability of the supply chain.

Alloga (Nederland) B.V.'s sourcing pattern, characterized by a concentrated portfolio of products imported from India, positions the company as a specialized logistics provider within specific therapeutic areas. This focus can enhance operational efficiency and expertise in managing these products. For Indian exporters, this presents an opportunity to strengthen partnerships with Alloga by ensuring consistent product quality, timely deliveries, and compliance with international standards. By aligning with Alloga's specific product requirements and quality expectations, Indian exporters can enhance their competitiveness and establish long-term, mutually beneficial relationships.

In the Netherlands, the Dutch Medicines Evaluation Board (CBG-MEB) is the primary regulatory authority responsible for the evaluation and supervision of pharmaceutical products. The CBG-MEB ensures that medicines available in the Netherlands are effective, safe, and of high quality. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for the marketing, import, and distribution of medicinal products. The marketing authorization pathway for Indian generics involves obtaining a marketing authorization from the CBG-MEB, which may include demonstrating bioequivalence to the reference product and compliance with Good Manufacturing Practice (GMP) standards.

Import licensing requirements in the Netherlands stipulate that pharmaceutical products must be authorized by the CBG-MEB before they can be marketed. Manufacturers and importers must hold a valid wholesale distribution authorization, which requires compliance with Good Distribution Practice (GDP) and GMP standards. GMP certificates recognized by the CBG-MEB include those issued by the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that manufacturing processes meet international quality standards, which is crucial for the safety and efficacy of pharmaceutical products.

Pharmaceutical products imported into the Netherlands must undergo batch testing to verify their quality, safety, and efficacy. Stability studies are required to ensure that products maintain their quality throughout their shelf life. Labeling requirements include providing information in Dutch, the official language of the Netherlands, and must comply with the EU's labeling regulations. Serialization mandates are in place to prevent counterfeit medicines and ensure traceability throughout the supply chain. These measures are essential for maintaining public health and ensuring that patients receive safe and effective medications.

Between 2024 and 2026, the Netherlands implemented several regulatory changes affecting pharmaceutical imports. These included stricter compliance requirements for Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP), as well as enhanced pharmacovigilance measures to monitor the safety of medicines post-market. Additionally, the Netherlands aligned its regulations with the European Union's Falsified Medicines Directive, introducing more stringent serialization and traceability requirements to combat counterfeit medicines. These changes aim to strengthen the safety and integrity of the pharmaceutical supply chain.

Alloga (Nederland) B.V.'s focus on importing finished pharmaceutical formulations in the therapeutic categories of Brand Names & OTC Products, Immunosuppressants, and Lipid & Metabolism indicates a strategic alignment with market demand. The substantial import value of Brufen, a nonsteroidal anti-inflammatory drug (NSAID), suggests a strong market demand for pain management and anti-inflammatory treatments. The inclusion of Leflunomide and Fenofibrate reflects a commitment to providing essential medications for chronic conditions such as rheumatoid arthritis and hyperlipidemia, respectively. This product strategy positions Alloga to meet critical healthcare needs within the Netherlands.

Alloga (Nederland) B.V. employs a sourcing strategy that focuses on importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The company's preference for finished products over active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market solutions that can be efficiently distributed within the Netherlands. India's compliance with international quality standards, such as GMP, aligns with Alloga's commitment to ensuring the safety and efficacy of the products it distributes.

Based on its product mix, Alloga (Nederland) B.V. serves multiple segments of the Netherlands market, including retail pharmacies, hospitals, and government tenders. The importation of both over-the-counter and prescription medications positions the company to meet the needs of various healthcare providers and patients. By offering a diverse range of pharmaceutical products, Alloga contributes to the accessibility and availability of essential medications across the healthcare system.

There is a realistic opportunity for new Indian suppliers to partner with Alloga (Nederland) B.V., particularly if they can offer high-quality finished pharmaceutical formulations that meet the therapeutic needs identified in Alloga's product strategy. Gaps in Alloga's current sourcing may exist in areas such as emerging therapeutic categories or innovative drug formulations. Indian exporters can explore these opportunities by ensuring compliance with international quality standards, providing competitive pricing, and demonstrating a commitment to reliable supply chain practices.

Indian exporters seeking to supply Alloga (Nederland) B.V. and the Netherlands market must obtain marketing authorization from the Dutch Medicines Evaluation Board (CBG-MEB). This requires compliance with Good Manufacturing Practice (GMP) standards, with certifications recognized by the EU, WHO, or PIC/S. Additionally, products must meet labeling requirements in Dutch and adhere to serialization mandates to ensure traceability and